6ER-005 Use of sacubitril/valsartan in patients with chronic heart failure

BackgroundRecommendations approved by the local Pharmacy and Therapeutics Committee (PTC) for the prescription of Sacubitril/Valsartan (SV) are: patients with chronic symptomatic heart failure (HF) (II–III grade following New York Association (NYHA)) with reduced left ejection fraction (LVEF 640 pg/...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A279-A280
Main Authors: Enríquez Olivar, L, López González, AM, Izquierdo Muñoz, S, Queipo García, E, Sánchez Sánchez, MT
Format: Article
Language:English
Subjects:
Heart failure
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundRecommendations approved by the local Pharmacy and Therapeutics Committee (PTC) for the prescription of Sacubitril/Valsartan (SV) are: patients with chronic symptomatic heart failure (HF) (II–III grade following New York Association (NYHA)) with reduced left ejection fraction (LVEF 640 pg/ml) seric levels to be treated with standard of care therapy: angiotensin converting enzyme inhibitors (ACE) or angiotensin II receptor blockers (ARB), in combination with beta-blockers (BB) and mineralcorticoid antagonists.PurposeTo evaluate the adherence to the recommendations of the PTC concerning the prescriptions of SV on hospital admission.Material and methodsA descriptive, observational and prospective study including patients treated with SV from March 2018 to July 2018 in a General Teaching Hospital.Variables considered were: sex, age, patient chronic and fragile (G3), according to the stratification of the regional Health Service, HF NYHA classification, LVEF, NT-proBNP, previous treatment with ACE inhibitors/ARBs, BB and mineralcorticoid antagonists at hospital admission and glomerular filtration rate (GFR).ResultsFifty-one patients were included: 84% (43/51) were men, average 69±11 years and 51% (30/51) were G3.According to the PTC’s recommendations: 26/51 (51%) patients with NYHA III and 20% (10/51) NYHA II grade. The median of NT-proBNP was of 2,396 pg/ml (247–49, 280), 31/51 (61%) patients had NT-proBNP levels registered in the electronic clinical record (ECR), 3/31 (10%) patients had NT-proBNP 35%. Ninety per cent of patients received ACE or ARB and 57% (29/51) received both BB and mineralcorticoid antagonists. Just 27/51 (53%) of patients were well-treated with standard care therapy (ACE/ARBs, BB and mineralcorticoid antagonists). Two per cent (1/51) of patients had GFR
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2019-eahpconf.602